Concourse Financial Group Securities, Inc. Exelixis, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

A detailed history of Concourse Financial Group Securities, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 3,361 shares of EXEL stock, worth $120,323. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,361

Previous 3,399 1.12%

Holding current value

$120,323

Previous $76,000 14.47%

% of portfolio

0.01%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$21.96 - $27.6 $834 - $1,048	-38 Reduced 1.12%	3,361 $87,000
Q2 2024 Jul 23, 2024	BUY	$20.34 - $23.73 $7,627 - $8,898	375 Added 12.4%	3,399 $76,000
Q1 2024 Apr 30, 2024	BUY	$20.17 - $23.93 $4,175 - $4,953	207 Added 7.35%	3,024 $71,000
Q4 2023 Feb 07, 2024	BUY	$19.25 - $24.13 $9,875 - $12,378	513 Added 22.27%	2,817 $67,000
Q3 2023 Oct 25, 2023	BUY	$19.04 - $22.74 $18,126 - $21,648	952 Added 70.41%	2,304 $50,000
Q2 2023 Aug 10, 2023	BUY	$18.17 - $20.48 $8,121 - $9,154	447 Added 49.39%	1,352 $25,000
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $700 - $834	43 Added 4.99%	905 $17,000
Q4 2022 Jan 30, 2023	BUY	$14.96 - $17.39 $3,455 - $4,017	231 Added 36.61%	862 $0
Q3 2022 Nov 15, 2022	SELL	$15.68 - $22.27 $11,775 - $16,724	-751 Reduced 54.34%	631 $10,000
Q2 2022 Aug 09, 2022	BUY	$17.44 - $23.16 $401 - $532	23 Added 1.69%	1,382 $29,000
Q1 2022 May 09, 2022	SELL	$17.03 - $22.67 $1,992 - $2,652	-117 Reduced 7.93%	1,359 $31,000
Q4 2021 Feb 07, 2022	BUY	$15.84 - $21.88 $4,276 - $5,907	270 Added 22.39%	1,476 $27,000
Q3 2021 Nov 09, 2021	BUY	$16.3 - $21.14 $11,279 - $14,628	692 Added 134.63%	1,206 $25,000
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $287 - $408	-16 Reduced 3.02%	514 $9,000
Q1 2021 May 13, 2021	SELL	$20.53 - $25.22 $4,865 - $5,977	-237 Reduced 30.9%	530 $12,000
Q4 2020 Feb 02, 2021	SELL	$18.39 - $24.8 $882 - $1,190	-48 Reduced 5.89%	767 $15,000
Q3 2020 Nov 13, 2020	BUY	$20.67 - $26.94 $806 - $1,050	39 Added 5.03%	815 $20,000
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $905 - $1,508	55 Added 7.63%	776 $18,000
Q1 2020 May 13, 2020	SELL	$14.46 - $21.8 $38,680 - $58,315	-2,675 Reduced 78.77%	721 $12,000
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $37,950 - $47,319	2,505 Added 281.14%	3,396 $60,000
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $53,322 - $68,312	-3,016 Reduced 77.19%	891 $16,000
Q2 2019 Aug 13, 2019	BUY	$18.93 - $24.75 $2,479 - $3,242	131 Added 3.47%	3,907 $83,000
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $254 - $321	-13 Reduced 0.34%	3,776 $89,000
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $44,894 - $71,700	3,289 Added 657.8%	3,789 $74,000
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $7,935 - $11,200	500 New	500 $9,000

Others Institutions Holding EXEL

# of Institutions

465

Shares Held

240M

Call Options Held

1.87M

Put Options Held

1.12M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account

Concourse Financial Group Securities, Inc. Exelixis, Inc. Transaction History